Abstract
The aim of the QUASAR trial was to determine the size and duration of any survival benefit from adjuvant chemotherapy for patients with colorectal cancer at low risk of recurrence, for whom the indication for such treatment is unclear.
| Original language | English |
|---|---|
| Pages (from-to) | 2020-2029 |
| Number of pages | 10 |
| Journal | Lancet |
| Volume | 370 |
| Issue number | 9604 |
| DOIs | |
| Publication status | Published - 15 Dec 2007 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Adjuvants, Immunologic
- Adult
- Aged
- Aged, 80 and over
- Antimetabolites, Antineoplastic
- Colorectal Neoplasms
- Combined Modality Therapy
- Female
- Fluorouracil
- Humans
- Leucovorin
- Levamisole
- Male
- Middle Aged
- Neoplasm Recurrence, Local
- Vitamin B Complex
Fingerprint
Dive into the research topics of 'Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver